This site is intended for US Healthcare Professionals only.
curve shape

neffy 1 mg is now available at your patients’ preferred local pharmacy.

$25 copay card
Majority of commercially insured patients pay $25*
Majority of commercially pdf
*Terms and conditions apply.

Hello neffy.Goodbye needles.

Now, your patients do not need to hesitate at the onset of symptoms of an allergic reaction.1-4
No needles. No hesitation.1,4Prescribe neffy today
MEET neffy
Gradient background
Gradient background
A green-teal gradient circle with a white magnifying glass icon looking at a chart-like "N" in the center of it

Explore the trial results behind neffy

Rapid effects on blood pressure and heart rate (key PD surrogate markers) within 1 minute, delivering changes comparable to IM injection products5,6†

SEE THE DATA
A green-teal gradient circle with a white icon of the neffy® (epinephrine nasal spray) bottle in the center of it

Designed to be small, easy to carry, and easy to use7,8

See how to use and store neffy, which provides intranasal delivery of the same epinephrine your patients rely on

DISCOVER neffy
A green-teal gradient circle with two white hands almost touching in the center of it

Supporting patient access to neffy

Try neffy in your practice and explore how you may be able to help your patients save by e-Prescribing through BlinkRx

START NOW

†The clinical meaning of PD responses observed in healthy subjects is unclear in the context of treating anaphylaxis. Clinical studies have not been conducted in patients with anaphylaxis.

IM, intramuscular; PD, pharmacodynamic.

References: 1. neffy [prescribing information]. San Diego, CA: ARS Pharmaceuticals Operations, Inc. 2. Ellis AK, Casale TB, Kaliner M, et al. Development of neffy, an epinephrine nasal spray, for severe allergic reactions. Pharmaceutics. 2024;16(6):811. 3. Casale TB, Ellis AK, Nowak-Wegrzyn A, Kaliner M, Lowenthal R, Tanimoto S. Pharmacokinetics/pharmacodynamics of epinephrine after single and repeat administration of neffy, EpiPen, and manual intramuscular injection. J Allergy Clin Immunol. 2023;152(6):1587-1596. 4. Kaplan H, Rooney E, Tanimoto S, Lowenthal R. Epinephrine via needle-free device would be administered faster after symptoms: results of a patient/caregiver survey. Presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; November 11, 2022; Louisville, KY. 5. Data on file. EPI-15 CSR. ARS Pharmaceuticals Operations, Inc. 2024. 6. Data on file. EPI-16 CSR. ARS Pharmaceuticals Operations, Inc. 2022. 7. Data on file. Human Factors Study. ARS Pharmaceuticals Operations, Inc. 2024. 8. Casale TB, Lockey R, Portnoy J, et al. Pharmacokinetics of self-administration of ARS-1 (neffy® nasal spray) 2.0 mg versus manual intramuscular (IM) epinephrine 0.3 mg by health care provider (HCP). Presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting; February 24, 2023; San Antonio, TX.

IMPORTANT SAFETY INFORMATION & INDICATION

+

IMPORTANT SAFETY INFORMATION

It is recommended that patients are prescribed and have immediate access to two neffy nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of neffy in the same nostril with a new nasal spray starting 5 minutes after the first dose.

INDICATION

neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 15 kg or greater.

neffy is for use in the nose only.

Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

Absorption of neffy may be affected by underlying structural or anatomical nasal conditions.

Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

The presence of a sulfite in neffy should not deter use.

neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

Most common adverse reactions are nasal discomfort, headache, rhinorrhea, dizziness, nausea, vomiting, throat irritation, nasal congestion, paresthesia, sneezing, upper respiratory tract congestion, epistaxis, rhinalgia, nasal dryness, dry throat, fatigue, and feeling jittery.

These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for neffy.